Atypical hemolytic uremic syndrome (aHUS) is a genetic ultrarare renal disease associated with overactivation of the alternative pathway of complement. Four gain-of-function mutations that form a hyperactive or deregulated C3 convertase have been identified in Factor B (FB) ligand binding sites. Here, we studied the functional consequences of 10 FB genetic changes recently identified from different aHUS cohorts. Using several tests for alternative C3 and C5 convertase formation and regulation, we identified two gain-of-function and potentially disease-relevant mutations that formed either an overactive convertase (M433I) or a convertase resistant to decay by FH (K298Q). One mutation (R178Q) produced a partially cleaved protein with no ligand binding or functional activity. Seven genetic changes led to near-normal or only slightly reduced ligand binding and functional activity compared with the most common polymorphism at position 7, R7. Notably, none of the algorithms used to predict the disease relevance of FB mutations agreed completely with the experimental data, suggesting that in silico approaches should be undertaken with caution. These data, combined with previously published results, suggest that 9 of 15 FB genetic changes identified in patients with aHUS are unrelated to disease pathogenesis. This study highlights that functional assessment of identified nucleotide changes in FB is mandatory to confirm disease association.
Atypical hemolytic uremic syndrome (aHUS) is a rare renal thrombotic microangiopathy disease characterized by mechanical hemolysis, platelet consumption, and acute kidney failure. 1 aHUS is associated with genetic abnormalities in the proteins of the alternative complement pathway 2 as well as anti-Factor H autoantibodies. 3 The mutations may induce either loss of function of key complement regulators (such as Factor H [FH], Factor I, or membrane cofactor protein [CD46]) or overactivity of the C3 convertase components C3 and Factor B (FB). Anti-C5 blocking antibody Eculizumab has revolutionized the management of aHUS, giving good results in patients with and without known complement genetic abnormality. 4, 5 Nevertheless, knowledge of the underlining genetic defect and its functional consequences is of importance for patients' management, especially when the decision for transplantation should be made. [5] [6] [7] Routine screening of the aHUS susceptibility genes led to the identification of a large number of mutations and rare variants. In-depth functional analyses are required to predict if the genetic change is related to the disease manifestation or just a fortuitous association. The majority of tested mutations had, indeed, a functional defect. 2 Nevertheless, five mutations found in aHUS patients-one mutation in FB, 8 one mutation in Factor I, 9 two mutations in FH, 10 and one mutation in decay accelerating factor (CD55) 11 -were reported to lack a functional defect, and the link with complement dysregulation for them remains unclear. 12 Experimental verification of functional consequences of a mutation is a time-consuming process. Therefore, there is a need to develop reliable in silico algorithms, validated with experimental data, to predict rapidly whether the discovered genetic change is pathogenic or not.
FB mutations in aHUS are rare, with a frequency of 0%-4% of the patients from different cohorts. [13] [14] [15] [16] To date, 15 FB genetic changes have been published 8, 13, 15, [17] [18] [19] [20] [21] (Table 1) , but functional data are reported for only 5 of them. 8, 17, 19 FB forms the alternative pathway C3 and C5 convertases interacting with two partners (C3b and Factor D) and cleaves two substrates (C3 and C5). The structures of most of these complexes are known, [22] [23] [24] and functional tests studying C3b binding and the activity of the C3 and C5 convertases are available.
Four aHUS FB mutations resulted in the formation of either hyperactive C3 convertase or a convertase unsusceptible to complement regulation mechanisms. 17, 19 In contrast, two FB polymorphisms at position 7 (R7Q and R7W) were found to be hypoactive compared with the most frequent FB variant R7. 25 The functional activity of FB, between R7 and R7Q variants, determines the arbitrary normal range. 25 The objective of this study was to characterize the functional consequences of 10 newly identified FB genetic changes (Table  1 ) and understand whether and how they are related to aHUS. We sought to compare the in silico algorithms to predict the outcome of a given genetic change, searching for one that shows a good agreement with experimental data.
RESULTS

FB Genetic Changes in the Normal Population
In the 1000 Genomes database, 26 32 polymorphisms of FB have been reported (Supplemental Figure 1) . Among them, three have been identified in aHUS patients (I217L Figure 1 ). The previously described mutation K298E 17 was also reported in this database as an extremely rare variant without reported frequency (rs121909748).
Structure Description
All identified mutations were mapped on the structures of FB, 23 C3bBD, 22 and C3bBb 24 ( Figure 1 , Tables 2 and 3 ). Three mutations (R113W, S141P, and R178Q) are in the Ba complement control protein domains. These residues are released with the Ba fragment after FB cleavage and absent in the active convertase C3bBb. The rare variant I217L is located in the linker between Ba and Bb fragments near the R234-K235 scissile bond. Five mutations are in the von Willebrand factor type A domain, which is responsible for the binding to C3b. V430I and M433I are close to the Mg 21 adhesion site. One mutation (K298Q) affects the same residue as the previously published mutation K298E. 17 P344L is far from any known binding site and located in a flexible proline/tryptophane-rich loop.
The last two variants (K508R and E541A) are in the serine protease domain of FB-on the same surface but not close to the catalytic triad Asp551, His501, and Ser674.
Expression of Recombinant FB
All recombinant proteins (except one) were generated and expressed successfully, with the expected molecular weight and concentration similar to the wild-type (WT) (Supplemental Figure 2 ). Obtained functional results are summarized in Table 2. R178Q was secreted as a partially cleaved protein by both human embryonic kidney 293T and Chinese hamster ovary cells (Supplemental Figure 2A) .
Binding to C3b
The interaction between recombinant FB and its ligand C3b was assessed by ELISA and in real time by surface plasmon resonance (SPR). The gain-of-function mutation D254G served as a positive control for increased binding. The binding of recombinant R7Q and R7W to C3b was about 40%-50% weaker than the WT as measured by both techniques (Figure 2 ). The binding variation between WT R7 and R7Q (lowest binding allotype) with C3b was considered as the normal range. The ELISA analysis did not show significant increase of the binding of any of the newly characterized mutations. The SPR interaction results (Figure 2) showed that only M433I led to a mild increase (1.38-fold increase) of C3b binding affinity (far below the 5.4-fold increase observed with the positive control D254G). S141P showed faster association but also faster dissociation of the formed complex. The remaining mutations were within the normal range as SPR curve profiles (Figure 2 , B-E) and binding affinity ( Figure 2F ). For R178Q, which was produced partially cleaved, no binding to C3b was detected by these techniques.
C3 Convertase Formation and Dissociation
Five different tests were used to monitor the formation and/or the dissociation of alternative pathway C3 and C5 convertases (Figures 3 and 4) .
The formation of (C3bBb-Mg 2+ ) C3 convertase was assessed in real time by SPR (Figure 3 ) and the combination of ELISA and Western blot 27 ( Figure 4A ). The formation of the C3/C5 convertase on cell surface (Figure 4 , B-E) and the dissociation of the C3 convertase on cell surface by FH ( Figure 4F ) were measured by hemolytic tests. The positive control in these tests was the gain-of-function mutation D254G, 17, 19, 28 which indeed, induced stronger formation of C3 convertase by SPR ( Figures 3A and 4A ) and enhanced erythrocytes lysis ( Figure 4B ) compared with the WT and formed a convertase resistant to dissociation by FH ( Figure 4F ). Also, K298E, known to form a convertase resistant to decay by FH, was included as an additional control. 17 The resistance to dissociation by FH of this mutation was confirmed by the hemolytic assay. The SPR test showed only very mild perturbation, potentially because of a weaker sensitivity of this assay. As expected, the R7Q polymorphism was hypoactive in terms of formation of the C3 and C3/C5 convertases ( Figures 3A and 4, A and B) , and the C3 convertase was decayed normally ( Figures 3A and 4F) . No functional activity was detected for the supernatant from mock-transformed cells.
The mutations could be classified in five groups according to their functional behavior ( Table 2) : (1) gain of formation of the C3 convertase by SPR and ELISA/Western blot assays (S141P, I217L, D254G, M433I, and K508R); (2) gain of formation of the C3/C5 convertase by hemolytic test (D254G and M433I); (3) resistance of the convertase to decay by FH (D254G, K298E, and K298Q); (4) lack of activity (R178Q); and (5) activity within the normal range (R113W, P344L, V430I, and E541A).
Complement Activation on Endothelial Cells
FACS analyses allowed estimation of the deposition of C3 fragments on endothelial cells (human umbilical cord vein endothelial cells [HUVECs] ) and, thus, the alternative pathway activation in FB-depleted serum reconstituted with recombinant FB ( Figure 5 , Table 2 ). Reduced C3 deposition was detected for R7Q and R7W compared with WT (R7), thus allowing for establishment of a normal range.
On resting HUVECs, only the positive control D254G showed increased C3 deposition, which was similar to the one observed when a blocking anti-FH antibody was added to serum ( Figure 4A ). On activated and heme-exposed cells, increased deposition was measured for the blocking anti-FH antibody, D254G, as well as K298E, K298Q, and M433I (Figure 5 , B and C). E541A showed increased C3 deposition on activated HUVECs but not on heme-exposed HUVECs (Figure 5 , B and C). R178Q had no functional activity in these tests ( Figure 5 , A-C). The remaining mutations showed either normal or reduced C3 deposition but were always in the normal range.
Terminal complement C5b-9 deposition can be measured on apoptonecrotic HUVECs when incubated with normal sera. 19, 29 Therefore, apoptonecrotic HUVECs were used as a model surface to study the activity of the alternative pathway C5 convertase in the presence of FB mutations. Because the Ba fragment does not participate in the C5 convertase activity, only the mutations within the Bb part as well as I217L were tested ( Figure 5D ). The two known gain-of-function mutations (D254G and K298E) as well as K298Q and M433I resulted in a significantly stronger C5b-9 deposition, whereas the remaining tested mutations showed levels similar to the WT.
Prediction for the Damaging Probability of FB Mutations
Four different algorithms were used to calculate the probability that each mutation will induce alterations of the protein structure and function (Table 3 ). The relation of the mutated position to an interaction site was used as an additional predictor. The consistency of predictions by those five methods was measured using the Cronbach's a-coefficient 30 (Supplemental Table 1 ) (a=0.6576). It shows only moderate agreement between the methods. Calculating Cronbach's a for all combinations of the four methods shows that Mutation Taster's disagreement with the rest is the greatest. Omitting it brings the criterion (a=0.8053) to a level indicating high consistency. Using PolyPhen, only 4 of 15 genetic changes were predicted to be damaging, contrary to Mutation Taster and Sorting Intolerant from Tolerant (SIFT), which predicted 8 of 14 and 10 of 15 changes as damaging, respectively. AlignGrantham variation (GV)/Grantham deviation (GD) returned 6 of 15 damaging scores. Although the GV/GD, SIFT, and interaction site involvement algorithms correlated well with the functional assay results, PolyPhen and Mutation Taster showed insignificant or no correlation (Table 4) . Combining these results with the analysis of agreement led to the conclusion that Mutation Taster does not contribute substantial information. However, the other four methods seem to complement each other. To make use of this fact, a consensus score was defined as the number of methods scoring positive for each mutation (score=0-4). The performance of this score and the optimal cutoff for classifying the mutations were estimated using receiver operating characteristic curve analysis (Supplemental Figure 3) . The area under the curve was 0.92 (95% confidence interval, 0.66 to 1.00; P,0.001). Optimal classification was achieved with a cutoff of consensus score.1 (sensitivity=85.7%; specificity=87.5%). This yielded one false positive case and one false negative case. Interestingly, the consensus score outperformed the other methods and equaled the binding site involvement (Table 4) .
Similar results were obtained for 17 mutations in the C-terminal 19 and 20 domains of FH, for which the functional defect was well characterized [31] [32] [33] (data summarized in ref.
2) (Supplemental Table 2 ).
Frequency of R32Q and R32W in aHUS Patients and Healthy Donors
The position 7-based alleles were studied for aHUS patients of the French aHUS cohort and French healthy donors. Healthy donors presented the allele frequency expected for the Caucasian population (Table 5) . When the aHUS patients allele frequencies were compared with healthy donor frequencies, there was no significant difference.
DISCUSSION
Identification of a genetic abnormality in aHUS patients is of importance for selection of a therapeutic regimen and transplantation decisions. The mutations in FH, C3, or FB, for which a clear functional consequence has been identified, affect the formation and/or the regulation of the C3 convertase. These defects translate to overactivity of the terminal complement pathway. As a result, the presence of FH mutations in patients' sera induces a spontaneous lysis of sheep erythrocytes, 34, 35 and the presence of FB or C3 mutations causes In the GV/GD column, 0 indicates no predicted defect, and a number$15 predicts functional defect. In the semantics of Mutation Taster, polymorphism means mutation without predicted functional significance. In the consensus score, one indicates that two or more algorithms suggested a functional defect, and zero indicates that less than two algorithms predicted affected functions.
enhanced C5b-9 deposition of apoptonecrotic endothelial cells. 19, 29 The pathogenic role of C5 convertase overactivation also explains the therapeutic efficacy of Eculizumab in aHUS. Eculizumab leaves the overactive C3 convertase untouched but blocks the C5 cleavage. 5 Therefore, an FB mutation should be defined as gain of function when it is able to form an overactive C3/C5 convertase or a C3 convertase resistant to decay by the regulators that is strong enough to translate the functional defect to the level of C5 cleavage on a cell surface. Gainof-function FB mutations were reported in 12 patients from five families and are associated with a severe outcome, leading to ESRD in the majority of the cases. 13, 15, [17] [18] [19] 21 Therefore, the presence of a FB mutation is considered as a bad prognosis for the disease. C3 levels are frequently below the normal range in these patients, suggesting active complement consumption in the plasma caused by C3 convertase overactivity. The aim of this work was to understand if this phenotype is shared between all identified FB genetic abnormalities and find out whether other FB mutations could be causative factors for aHUS.
We used 10 different binding and functional tests for the formation of the C3 and C3/C5 convertases and the resistance of the C3 convertase to dissociation by FH to classify 10 previously uncharacterized aHUS-associated genetic changes as potentially disease-causing or benign.
We confirmed the previous reports that D254G and K298E are gain-of-function mutations forming overactive C3 convertase and/or convertase resistant to decay by FH. 16, 18 A similar phenotype is shared by two newly characterized mutations (M433I and K298Q). K298Q (removal of positive charge) had a milder effect compared with K298E (exchange of a positive charge with a negative charge). This result suggests that the positive charge at this position is of critical importance for the competition between FH and FB, which is in agreement with the structural data. 36 In fact, all gainof-function mutations appeared to be directly located within the C3b binding site (D254G and K325N) or buried beneath it (F261L) or located in the area important for the electrostatic repulsion between FB and FH. In agreement with the experimentally determined functional consequences, C3 levels were low in all patients with these mutations for which data were available, indicating alternative pathway consumption in vivo. Therefore, low C3 levels in the patient together with a mutation localized in an important interaction site are a strong indication that the mutation may be a gain-of-function. Nevertheless, for three patients from this study (R113W, R178Q, and K508R) and two unrelated patients with a previously published mutation (L408S), the low C3 levels could not be explained by a gain of function of the respective FB mutation.
The mutation R178Q showed complete lack of functional activity and was produced as a cleaved recombinant protein.
Unfortunately, no plasma samples were available from this patient to test if it happens in vivo or is an in vitro artifact. It could be hypothesized that intrinsic propensity for cleavage could facilitate the in vivo transition between C3 proconvertase C3bB and active convertase C3bBb, which would explain the C3 consumption found in the patient. Three genetic changes (R113W, P344L, and V430I) had either normal or slightly reduced C3b binding and convertase formation; the formed convertase was decayed normally by FH, and the C3 fragment deposition on endothelial cells was in the normal range. This benign phenotype could be because of their localization distant from known binding sites and explains why, in two of three cases, they were found in patients with normal C3 levels.
Four genetic changes (S141P, I217L, K508R, and K541A) had an incomplete phenotype. One or more performed tests showed increased binding or function, but the results were inconsistent between the different approaches. Moreover, neither of these mutations resulted in concomitant increase of the C3 fragments deposition on activated and heme-exposed endothelial cells and enhanced C5b-9 deposition on apoptonecrotic cells. Therefore, they do not fulfill the criteria set to consider a genetic change as a gain of function. Among the carriers of these genetic changes for whom data are available, only one patient, with K508R, had low C3 levels. Another patient with K508R had normal C3 levels, suggesting that this genetic change is not necessarily responsible for the C3 consumption. Therefore, the functional consequence of these genetic changes, if any, is mild and less likely to predispose directly to the aHUS pathogenesis. In addition, in two of these patients, additional Factor I mutations were identified, which could be the disease-predisposing factor rather than the genetic change in FB.
When an identified genetic change in a cohort is not found in the corresponding healthy controls, 1000 Genomes and other databases for genetic variants should be consulted to exclude that the identified genetic change is just a rare variant unrelated to the disease, which seemed to be the case of I217L, K508R, and E541 described here. The incomplete phenotype observed for these polymorphisms suggests that they may represent risk factors affecting the aHUS penetrance and severity but cannot be considered as disease-causing mutations. Studies with large aHUS cohorts and ethnically matched healthy donors are needed to establish if the frequency of these polymorphisms is increased in the patients compared with healthy controls.
The fact that a mild reduction of C3b binding and FB functional activity was detected for certain mutations is intriguing. The two normal variants, Q7 and W7, are reported 25 and confirmed here to be hypoactive compared with R7. Therefore, we sought to investigate if FB hypoactivity is associated with aHUS. No difference was found in the frequency of R7, Q7, and W7 in the French cohort of adult aHUS patients and French healthy volunteers, suggesting that the FB hypoactivity is not associated with this disease. Moreover, these polymorphisms did not differ among aHUS patients and healthy donors in a study of 501 complement-related single-nucleotide polymorphisms in 47 complement genes. 37 Of note, R7 is the most frequent polymorphism at this position, most of the FB mutations in the patients are found on R7 background, and the recombinant WT used in this study carries R at position 7. The observed magnitude of function change of R113W, P344L, L408S, and V430I compared with the hypoactive variants is small and not at the level that we would expect to cause aHUS on its own.
Based on our experimental data, it could be concluded that eight newly characterized FB genetic changes are most likely benign variants rather than disease-associated mutations. Interestingly, in 10 of 28 patients, the FB genetic changes were associated with rare variants or mutations without identified functional consequences in the other tested complement genes or ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). At the opposite of our series, most of the aHUS patients in a recently described subgroup with combined mutations have at least one functionally relevant genetic change. 38 This information is critical for analyses of the phenotype of patients and prediction of the survival or the outcome of a particular therapeutic regimen.
Functional studies are frequently unavailable to inform physicians of the possible relation of a newly identified genetic change with the disease. Therefore, bioinformatics tool(s) could be useful to get a prediction for the mutations role and guide the treatment decision. Unfortunately, the four prediction algorithms tested here agreed for only about one third of the mutations and gave discordant data for the rest. Performed statistical analyses suggested that none of these algorithms could be used confidently as a stand-alone approach because of incomplete agreement with the experimental data. The prediction efficiency was improved when the worseperforming method (Mutation Taster) was excluded, and a consensus score was calculated for the remaining three methods (PolyPhen, SIFT, and Align-GV/GD). Adding to this score the information on whether the genetic change falls within a known functional site (i.e., the area of the molecule important for ligands binding or functional activity) substantially improves the prediction. Nevertheless, the bioinformatics evaluation of the potential functional effect of a mutation should be taken with caution, because even the improved score proposed here gave one false positive and one false negative result for 15 analyzed FB mutations. Similar results were obtained for the mutations in the C terminus of FH, well known for their functional defect and association with aHUS. 2, [31] [32] [33] In conclusion, although some FB mutations induce complement overactivation and predispose to aHUS, others have a normal functional activity and hence, are benign and unlikely to be related to the disease. In-depth screening of all susceptibility genes as well as for the presence of anti-FH antibodies is necessary in all patients with identified FB mutations to identify other abnormalities affecting the disease occurrence, especially in the presence of low C3 levels. The status of the genetic change identified in aHUS needs to be carefully analyzed to prove the pathogenic role in the disease. We Figure 5 . Complement activation on endothelial cell surface. C3 deposition on (A) resting, (B) heme-exposed, or (C) TNFa/IFNgactivated HUVECs incubated with FB-depleted serum, reconstituted with the recombinant FB, and measured by flow cytometry (n=3-6). The C3 deposition from the WT was taken as one, and the values obtained for the remaining mutations were expressed as a fold difference compared with the WT. The supernatant from mock-transformed cells (white bar) is used as the negative control, and D254G and WT+FH blocking antibody Ox24 (hatched bars) are used as positive controls. (D) C5b-9 formation on apoptonecrotic HUVECs. After incubation with FB-depleted serum reconstituted with recombinant FB, the cells were probed for C5b-9 deposition by flow cytometry (n=3). The C5b-9 formation from the WT was taken as one and compared with the tested mutations. *P,0.05; **P,0.001, Mann-Whitney nonparametric test calculated with GraphPad Prism 5.
suggest that rare variants in which frequency is not increased in the patients cohorts and mutations without functional consequences should not be included in the patient management.
CONCISE METHODS
In Silico Analyses
PyMol (http://www.pymol.org/) and Chimera software 39 (http:// www.cgl.ucsf.edu/chimera) were used for structural data analyses. The probability that a genetic change induces an alteration of the protein structure and function was calculated with the following software: PolyPhen (http://genetics.bwh.harvard.edu/), 40 Marinozzi_et_al_final. doc, Align-GV/GD (http://agvgd.iarc.fr/), 41 Mutation Taster (http:// www.mutationtaster.org/), 42 and SIFT (http://sift.jcvi.org/). 43 The 1000 Genomes database 26 was searched for the presence of each identified FB genetic change to confirm the mutation status.
The pairwise contingency tables significance was determined using Fisher's exact test (P.0.05), and the correlation of the methods was estimated using the correlation coefficient. To test the internal consistency of the prediction by the battery of methods, the Cronbach's a-coefficient was calculated for all five methods together and all combinations of four methods to determine the contribution of each one by omitting it. A consensus method was proposed based on the number of methods predicting functional effects of each mutation. Its performance was tested against the in vitro-determined functional effects using receiver operating characteristic curve analysis. Using the Yuden J index, a cutoff was determined for the consensus score to classify the mutations as deleterious. All calculations were performed using MedCalc v12 software.
Recombinant FB Production and Characterization
The plasmid-containing recombinant FB construct and the mutagenesis protocol were described previously. 19 Proteins were expressed in human embryonic kidney 293T cells after transfection with Gene Juice lipotransfection reagent (Calbiochem). Serum-free supernatant, containing recombinant proteins, was harvested after 3 days of culture. A detailed description is given in Supplemental Material.
The integrity of recombinant WT and FB mutants was tested by Western blot (precasted gels and rapid transfer system iBlot by Invitrogen). Proteins in the culture supernatants were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with an in-house biotinylated polyclonal sheep anti-human FB antibody (Abcam, Inc.) followed by streptavidin-horseradish peroxydase (Amersham) and ECL substrate (GE Healthcare).
The FB content was assessed by sandwich ELISA using immobilized polyclonal sheep anti-human FB antibody (Abcam, Inc.) for capturing and biotinylated sheep anti-human FB followed by streptavidin-horseradish peroxydase (Dako) for detection as described previously. 19 Plasma-derived FB (Comptech, Tylor, TX) served as a standard.
C3b Binding Characterization
The ELISA approach for C3b-FB interactions was performed as previously described. 19 The interaction of WT and mutant FB with C3 was also analyzed using SPR technology with ProteOn XPR36 equipment (Bio-Rad). C3b was coupled to the GLC biosensor chip using standard amidecoupling technology. The recombinant WT and mutant FB were used as an analyte at concentrations 650, 325, 162.5, 81.25, and 40.625 pM and injected at 50 ml/min in Mg 2+ -containing Hepes buffer (10 mM Hepes [pH 7.4], 50 mM NaCl, and 10 mM MgCl 2 ) over the C3b-bearing surfaces and an empty activated/deactivated flowcell as a control. Data were analyzed using ProteOn Manager software, and the data from the blank flowcell were subtracted. Kinetic parameters were calculated by fitting the obtained sensorgrams into two state interaction models as described. 25 
FB Functional Assays
FB hemolytic activity and dissociation of the C3 convertase by FH were tested as described previously. 19 In addition, C3 convertase (C3bBb-Mg 2+ ) formation assays, based on SPR 17, 25 or ELISA/Western blot, were performed to assess the convertase formation by different approaches. 27 A detailed description is given in Supplemental Material.
Endothelial Cell Assay
Resting, TNFa/IFNg-activated, heme-exposed, and apoptonecrotic HUVECs were prepared as described 19, 29, 44 and incubated with 50 ml FB-depleted serum (CompTech) and 100 ml recombinant WTor mutant FB supernatants containing equal amounts of FB. Cells were labeled with anti-C3c (Quidel, San Diego, CA), anti-C5b9 neoepitope (a gift from Paul Morgan, Cardiff, UK), mAbs, or a control mouse IgG1 followed by phycoerythrin-labeled secondary antibody 
Genetic Analyses
Genomic DNA from each patient from the French adult aHUS cohort or healthy donors was obtained from peripheral blood leukocytes. The frequencies of R7, Q7, and W7 (rs12614 and rs641153) were assessed by a direct sequencing of exon 2 of FB as described before for mutations identification. 19 Screened individuals signed an informed consent, and the project was approved by the local ethical committee according to the Declaration of Helsinki. 
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